|Bid||212.54 x 800|
|Ask||212.58 x 800|
|Day's Range||208.81 - 214.48|
|52 Week Range||150.37 - 236.62|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||12.11|
|Earnings Date||Jun 27, 2019 - Jul 1, 2019|
|Forward Dividend & Yield||2.96 (1.69%)|
|1y Target Est||218.68|
The beverage giant's $4 billion bet on Canopy Growth is only the first step in building a leading global alcohol and cannabis enterprise.
Constellation Brands Inc is engaged in the beverage industry. The dividend yield of Constellation Brands Inc stocks is 1.43%. Constellation Brands Inc had annual average EBITDA growth of 24.80% over the past ten years.
After looking like they were set to break down, shares of Canopy Growth (NYSE:CGC) have been surging over the past few trading sessions. As such, CGC stock is up almost 20% over the past five days and on the cusp of breakout territory, with higher prices on many bulls' radar.Source: Shutterstock What so suddenly has CGC stock back in investors' good graces? To be fair, the company didn't really do anything to fall out of their good graces. Rather, it was simply the fading momentum of marijuana stocks at the time.However, momentum was restored in Canopy Growth stock once reports began circulating about its intention to purchase Acreage Holdings (OTCMKTS:ACRGF). The deal is for $300 million in cash and swelled to $3.4 billion once Canopy included 0.58 shares for each subordinate voting share of ACRGF.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Digital Ad Stocks That Deserve Your Attention Right Now Investors are viewing the deal favorably as Acreage Holdings has exposure in 20 different U.S. states. In other words, it's Canopy's way of pushing into the U.S. This comes as it focuses on its future and growing its market share. At the end of the day, market share is a very important component to the cannabis industry. That's one reason why Canopy is considered the leader of this group. Trading CGC StockThe charts for CGC stock look a little busy here, but each level is relevant. The recent action has shown a return of momentum to Canopy Growth stock, but also names like Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON), among others. It's even given a boost to names like Constellation Brands (NYSE:STZ), which has a near-40% stakes in CGC.That momentum has carried CGC stock into a potentially large breakout area over $48. Where can it go? One analyst says Canopy could run to $72, implying about 90% upside from current levels. Can it actually get there?$48 is the first key test. In the last three trading sessions, CGC stock reclaimed its 20-day and 50-day moving averages as well as prior uptrend support (blue line No. 1). It also cleared prior downtrend resistance (blue line No. 2) and key resistance at $48. Now hovering near $48.25, it's important that CGC stock doesn't give up these recent gains.Whether it can burst through its prior highs near $59 and run to $72 is currently unknown. But if it wants any shot at doing even that, it needs to hold over some of these key levels that it just cleared.Here's what to watch: $48 and prior downtrend resistance (blue line No. 2). According to the RSI, CGC stock is not overbought even after its strong rally over the past few days. According to its MACD reading, momentum is returning to the bulls' favor and could have a lot of upside going forward. Ideally we would see a continuation higher or consolidation near current levels, before a pullback to $48 that holds as support.If $48 soon acts as resistance, bulls need to see the backside of prior downtrend resistance act as support. Bottom Line on Canopy Growth StockIf investors feel that there is momentum in cannabis stocks, then CGC stock is certainly one of the top considerations to ride that wave. In the end though, this is a speculative group and investors have to remember that going forward. This isn't some blue chip stock with a reasonable valuation and strong cash flows.Last quarter (Q3, fiscal 2019), the company had $60.8 million in revenue. That's roughly the same total as it did for all of fiscal 2018. Clearly the growth is very impressive, but we're talking about a company that has consensus expectations for $176 million in sales this year vs. a market cap of more than $16 billion.Granted, estimates call for more than $600 million in sales in fiscal 2020 (which starts in one quarter), but this is still a lofty valuation. That's why M&A deals (such as with Constellation) are so important. It puts billions of dollars into Canopy's coffers, allowing it run its operations and make deals like it did for ARCGF. * 10 High-Yielding Dividend Stocks That Won't Wilt It's a speculative group, but Canopy is among the best in the business.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post Is Canopy Growth Stock Set to Break Out and Rally 90%? appeared first on InvestorPlace.
The alcoholic-beverage company owns 38% of Canopy Growth, which agreed to buy the U.S. pot seller Acreage Holdings once cannabis becomes legal under U.S. law.
Even in a space with as much excitement as marijuana stocks, Aphria (NYSE:APHA) stood out for having as much drama as a cable TV show. If you're a trader, APHA stock has been a dream lately. The stock rocketed from $8 to $16 in a month last summer. It then lost as much as 75% of its value, plummeting to $4, after a series of short seller reports. Since then, the stock has bounced 150% off the lows to return to the $10 level, before earnings sent it falling once more.Source: Shutterstock After all the excitement, what's next for APHA stock? And have the company's recent moves made it investable again, or is Aphria only appropriate for the most steel-nerved traders? Fallout From the Bearish Short Seller's ReportsA few months ago, short sellers hit APHA stock with heavy fire. Bearish analysts published reports suggested that Aphria's management had engaged in unscrupulous behavior.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe short sellers suggested that Aphria was engaged in all sorts of questionable if not worse activity. The short sellers said that the company had bought phantom assets in Latin America, engaged in various double-dealing and related party transactions, and numerous other red flags.Aphria's board of directors engaged an independent special committee to investigate the accusations. The special committee found some troubling factors, but its results also exonerated the company in various ways. Arguably the most important finding was that the committee confirmed that Aphria's Latin American assets in fact exist and are progressing toward commercial activity. * 7 Tech Stocks With Too Much Risk, Not Enough Upside The committee suggested that Aphria paid near the top end of a reasonable price range for the assets, but that there is a real business there, unlike the short seller's reports which had claimed these transactions were largely imaginary. New Management for APHA StockHowever, Aphria wasn't blameless either. The board disclosed that: "it appears that certain of the non-independent directors of the Company had conflicting interests in the Acquisition that were not fully disclosed to the Board."Probably in conjunction with that, Aphria has seen major management changes. Former Aphria CEO Vic Neufeld has stepped down, as well as Co-founder Cole Cacciavillani. Neufeld in particular was implicating in several of the alleged misdeeds that the short sellers identified.In his place, Aphria has appointed an interim CEO. Irwin Simon is now in charge, at least for the time being. Simon led Hain Celestial (NASDAQ:HAIN) for more than two decades, helping that company take a dominant position in the natural and organic foods space. While it is obviously a weak spot for Aphria not to have a permanent CEO in place yet, Simon seems to have capable hands to manage the company while it recovers from the reputational blows it suffered recently. Aphria Has a Rough Earnings ReportAs William White pointed out, Aphria plummeted on April 15 after an earnings report "with losses per share of 20 Canadian cents. This is a drop from the company's earnings per share of 8 Canadian cents from the same time last year. It was also bad news for APHA stock by missing analysts' losses per share estimate of 4.5 Canadian cents for the quarter."Revenue was up, but overall sales numbers fell. The market was unimpressed, and the stock is now down around 24% since the report.Back in December, new upstart cannabis firm Green Growth Brands (OTCMKTS:GGBXF) bid to acquire Aphria. This was a highly unusual deal for several reasons. Among them, Green Growth brands itself had just gone public as the merger of several other firms. Additionally, Aphria had a significantly larger market cap than Green Growth, making it a rather odd target for a takeover offer.After the earnings tumble, Green Growth stepped away from their takeover attempt. It may be good for Aphria that another element of uncertainty is gone, but it's hardly unequivocal good news overall. APHA Stock VerdictIt's good that Aphria has cleaned house. That was a necessary and important first step in recovering the market's trust in Aphria going forward. But there's still a lot to be uncertain of.Particularly in a market where so many of the big leaders in the space have deals with credible partners, it's easy to take a pass on APHA stock. Cronos (NASDAQ:CRON) has Altria (NYSE:MO) while Canopy Growth (NYSE:CGC) has partnered with Constellation (NYSE:STZ). Meanwhile, Aurora (NYSE:ACB) doesn't have a major partner yet, but its management team hasn't given us any big reasons to doubt its credibility either.The marijuana stock sector is the Wild West right now. Many of the companies out there are going to crash and burn in coming years. Aphria's efforts to clean up their act are appreciated. But in such a risky sector, at least for the time being, it's advisable to stick to more trustworthy leaders in the cannabis space.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post After the Drama, Where Is Aphria Headed Now? appeared first on InvestorPlace.
Ever since the cannabis craze hit Wall Street back in mid-2018, I've been pounding on the table saying that the best marijuana stock to buy in the group is Canopy Growth (NYSE:CGC). The logic is simple: In addition to being the biggest player in the industry, CGC stock has long had one thing that no other cannabis company has -- $4 billion in cash from Constellation Brands (NYSE:STZ).Source: Shutterstock That $4 billion gives Canopy unprecedented visibility into being one of the industry's long-term winners through early, aggressive, and large investments. As such, I have consistently reasoned that CGC stock belongs in every cannabis-related portfolio.This bull thesis got a big boost in mid-April. Canopy struck a deal with major U.S. cannabis operator Acreage to buy that company for $3.4 billion once cannabis is legalized nationwide in the U.S.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor those who don't follow this industry closely, that's a big deal. Canopy is the star player in the legal Canadian cannabis market. But the Canadian market is peanuts. The big deal here is the U.S. market. Depending on who you ask, that market is about tenfold the size of the Canadian market.Thus, the big question for Canopy and other Canadian pot stocks is whether or not these companies can replicate their success in the U.S. * 7 Strong Buy Stocks the Street Loves Canopy just answered that question in emphatic fashion, and the market is reacting favorably. CGC stock popped roughly 10% on the news.In the big picture, thanks to a $4 billion early investment from Constellation Brands, Canopy has given itself unprecedented visibility into being a long-term cannabis market leader. Right now, following the Acreage deal, that visibility is as strong as ever. Consequently, the long-term bull thesis for CGC is likewise as strong as ever. The Acreage Acquisition Is Big NewsThere's a reason CGC popped 10% in response to the company agreeing to acquire Acreage. In plain English, it positions the company to fully capitalize on the $100 billion U.S. cannabis market from the onset.First, some context. The whole Wall Street cannabis craze has been largely centered around one thing: the nationwide legalization of cannabis in Canada in late 2018. Roughly speaking, that single catalyst turned the big four Canadian pot stocks -- Canopy, Aurora (NYSE:ACB), Tilray (NASDAQ:TLRY) and Cronos (NASDAQ:CRON) -- from relatively unknown companies to Wall Street household names with multi-billion dollar market caps.But, while Canadian market legalization was the catalyst, it wasn't the prize. The prize here is the U.S. market, which most estimates put at a $100 billion opportunity, versus $10 billion in Canada. The consensus thesis is that, with cannabis fully legal throughout Canada and hemp legal throughout the U.S., it's only a matter of time before cannabis is fully legal across the entire U.S. The big question is whether or not Canadian cannabis giants like Canopy will be able to capitalize on the big U.S. opportunity when it comes knocking.Canopy just answered that question. By agreeing to acquire Acreage -- a major U.S. cannabis operator with dozens of dispensaries and cultivation sites across 20 states -- Canopy has positioned itself to capitalize on the $100 billion U.S. cannabis market opportunity from the onset. That is, as soon as cannabis is fully legal across the U.S., Canopy will be everywhere through Acreage -- and ready to dominate the U.S. market like it's dominated the Canadian market.That's a big deal. Indeed, it paves the path for CGC to head materially higher in a long-term window. Canopy Growth Stock Has Long-Term UpsideMy long-term bull thesis on Canopy Growth stock is that, if this company can successfully maintain its leadership position as the cannabis industry goes global and matures, then this is a $100 billion company in the making. With more visibility than ever to U.S. market domination, that long-term bull thesis looks about as good as ever.The details of my analysis behind the $100 billion number can be found here. But the short recap is pretty easy to understand. At scale, given current consumption trends, the recreational cannabis market could one day be as big as the alcoholic beverage and tobacco markets. What's more, if you consider the medical opportunity, then the aggregate global cannabis market will easily one day be as big as, if not bigger than, the alcoholic beverage and tobacco markets.The top dogs in those two industries have $100 billion-plus market caps. Witness Anheuser-Busch (NYSE:BUD) or Altira (NYSE:MO). Thus, it's only reasonable to assume that the top dogs in the global cannabis industry at scale will be $100 billion-plus companies too.Given its early leadership position, huge financial resources, aggressive management team, large growing capacity, and global distribution network, Canopy has all the tools necessary to turn into a top dog in the global cannabis industry in a decade. Now, Canopy also has visibility to be a top dog in the U.S. market. Thus, this company continues to take steps towards securing global leadership.So long as the company remains on that path, CGC stock will remain on an uptrend towards a $100 billion valuation. * 10 Dividend Growth Stocks You Can't Miss Bottom Line on CGC StockThere are a lot of pot stocks out there, but none of them have as much long-term visibility as Canopy Growth. Given this, if you're buying into the cannabis industry with a multi-year horizon, CGC stock is the best pick in the industry, without question.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post This Is Why Canopy Growth Is the Best Pot Stock appeared first on InvestorPlace.
Constellation Brands, Inc. Class A (NYSE:STZ) and Canopy Growth Corp (NYSE:CGC) have announced that they have agreed to make some changes to various warrants and rights. The new agreement to change some of the warrants and rights that influence their partnership is believed to have been influenced by Canopy’s plans to acquire Acreage Holdings Inc […]The post Constellation Brands, Canopy Growth Sign Deal To Revise Warrants appeared first on Market Exclusive.
The annual marijuana day celebration on April 20 led to a crash of delivery websites, including the biggest legal delivery app, Eaze, as companies struggled to keep up with demand.
One of the big themes in the cannabis sector in 2019 has been increased Wall Street coverage. Specifically, Wall Street firms were largely unwilling to cover cannabis stocks in 2018 given the industry's relative newness, rampant investor speculation and lack of fundamental tangibility. But, things have changed for marijuana stocks in 2019. The industry is less new. There's less speculation. The fundamentals have become significantly more tangible. As such, Wall Street firms have more broadly launched coverage on pot stocks in 2019.Source: Shutterstock One big firm that just initiated coverage on pot stocks is Bank of America. Their take? Of the Big Four pot stocks -- Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) -- the only two worth buying right now are Canopy and Aurora.This isn't an isolated viewpoint. According to TipRanks data, 10 analysts cover CGC stock, while eight analysts cover ACB stock. Of those 18 ratings between CGC and ACB, none of them are Sell ratings. Instead, the consensus rating on CGC stock is "Moderate Buy" while on ACB stock, it's "Strong Buy."InvestorPlace - Stock Market News, Stock Advice & Trading TipsMeanwhile, a third of the nine analysts who cover CRON stock have a "Sell" rating on the shares. The consensus rating is a "Hold." Half of the 10 analysts that cover TLRY stock have a "Sell" rating on the name. The consensus rating on TLRY is a "Hold," too.In other words, the broad consensus among Wall Street firms is that when it comes to the cannabis space, investors should buy CGC and ACB, and forget about CRON and TLRY for the time being. I largely agree with consensus Wall Street view. Here's why. Why Buy CGC Stock?The plain answer here is you buy CGC stock because this company has the most visibility today among all pot stocks to one day transform into a long term market leader. * 7 High-Risk Stocks With Big Potential Rewards Canopy has everything you'd want in an early-stage leader in a big-growth market. Sales leadership? They dwarf everyone else in the space when it comes revenues. Growth? They are growing just about as fast as anyone in the space, despite a much bigger base. Production leadership? They sell far more kilograms of cannabis than anyone else, and have among the largest production footprints in the world. Market expansion? They are pushing aggressively into the U.S. hemp market. Confident leadership? CEO Bruce Linton just said that Canopy will generate over C$1 billion ($748 million) in sales over the next 12 months. Celebrity connections? They have ties with Seth Rogen, Snoop Dogg, and Martha Stewart.Above all else, though, Canopy has the financial resources and firepower to sustain and even grow its early lead. A few quarters ago, alcoholic beverage giant Constellation Brands (NYSE:STZ) poured $4 billion into Canopy. The company still has $3 billion of that left on the balance sheet. That's almost double what any of its competitors have in terms of cash on hand.While 2018 saw a blockbuster year (with nearly $14 billion raised) for cannabis investments, 2019 is on pace to blow past that total, according to cannabis research provider New Frontier Data. Click to EnlargeThus, Canopy has far more firepower than anyone else in this space to invest in growth opportunities, expand operations, expand production, acquire smaller players, so on and so forth. As such, the company does reasonably project as a long-term leader in the global cannabis market, and that's why buying CGC stock today makes sense. Why Buy ACB Stock?The plain answer here is you buy ACB stock because this is the cheapest pot stock in the group for reasons that are most likely temporary.On a pure valuation basis, ACB stock is as cheap as it gets in the cannabis space. Across every metric -- trailing sales, forward sales, market cap per kilogram, annualized revenue -- ACB stock is considerably cheaper than its peers. We are talking a 20%+ undervaluation gap. * 7 Stocks to Buy for Spring Season Growth This relative undervaluation has nothing to do with operating fundamentals. Aurora is big, with the second-largest sales base in the market behind Canopy. The company controls about 20% of the Canadian adult-use market. They also have tremendous production capacity (Aurora has 500,000 kilograms per year in funded capacity) and gross profit margins are among some of the healthiest in the business.Instead, the relative undervaluation in ACB stock has to do with balance sheet. Specifically, unlike peers Canopy and Cronos, Aurora hasn't scored a big investment from a consumer staples giant. Thus, the balance sheet isn't overflowing with billions of dollars to help fund growth. Instead, Aurora has just over $100 million in cash on hand.This won't last forever. Aurora is a big and leading company in the rapid growth cannabis space. The stock is also trading at a huge discount to peers. Thus, it truly is only a matter of time before some big consumer staples company pumps a billion bucks in here, or more. When that happens, the relative undervaluation gap will disappear, and ACB stock will rally in a big way. Bottom Line on CGC Stock and ACB StockThe cannabis sector reeks of long-term potential. But, a lot will happen between now, and when the market matures, and that means that investors need to choose wisely when investing in pot stocks this early in the game.Investment translation? Only buy CGC stock and ACB stock. There are very good reasons to own those two pot stocks here and now, and they should rally over the next several quarters.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Why These Are the Top 2 Pot Stocks to Buy Right Now appeared first on InvestorPlace.
How far off is Constellation Brands, Inc. (NYSE:STZ) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting t...
The top beer stocks have a market cap exceeding $2 billion and are trading on leading American stock exchanges. Here are the top beer stocks of 2018.
Constellation Brands is boosting its U.S. beer business while betting that marijuana products will deliver big sales.
It's 420. TheStreet's Jim Cramer discusses Canopy Growth, Tilray, Constellation Brands and other investing opportunities in the cannabis sector!
A company that jumps to a major stock exchange is the "rocket ship" event of marijuana stocks. It can send shares soaring to a whole new level -- into the stratosphere.This is what my research identifies. Companies in prime position for takeoff… but still before they blast off. The best way to show you what I'm talking about is to give you an example.There's a particular chart that marijuana execs are obsessed with right now -- and I can't blame them:InvestorPlace - Stock Market News, Stock Advice & Trading TipsCronos Group (NASDAQ:CRON) soared nearly 10,000% in less than three years. It's significant because it was the first of the Canadian cannabis stocks to make the leap to a major U.S. stock exchange. It began trading on the NASDAQ in February 2018.But let's go back to December 27, 2017 -- prior to the company announcing it had filed to list on the NASDAQ. It was trading on the smaller OTC market under the symbol PRMCF.In a newsletter I was writing at the time, I recommended Cronos when it was trading at $5.50 per share on the OTC exchange. Given our short-term trading strategy, we sold the stock in just 48 hours -- and locked in a nearly 50% profit!Pretty good for a couple day's work. * 5 Dividend Stocks Perfect for Retirees It was a fantastic short-term win, but now let's look at Cronos with the longer-term strategy I employ today. In a monster trend like what marijuana stocks are enjoying, we want to hold for the huge profits that can go along with it.On February 27, 2018, Cronos jumped to the NASDAQ and made history as the first Canadian marijuana company to list on a major U.S. exchange. The stock closed the Friday before the announcement at $7.01. One week after the announcement, it traded as high as $10.39 -- a rally of nearly 50%.Almost three months later on May 23, 2018, Cronos made another jump within Canada when it moved from the TSX Venture Exchange to the major Toronto Stock Exchange (TSX). Two weeks later, the stock was up 28%. (Note: Most Canadian marijuana stocks begin their public lives on the TSX Venture Exchange. The jump to the TSX is the equivalent of uplisting from the OTC to the NYSE in the United States.)As you can see in the chart above, both jumps resulted in big short-term profits. But you can make a lot more money by holding on for the longer-term surge that begins with the jump.Things change in the blink of an eye when tiny cannabis stocks go from having 30 million people following them in Canada to more than 300 million in the United States. Wall Street banks like Morgan Stanley and TD Ameritrade poured over $200 million in Cronos.What happened next was a chain reaction. The story appeared everywhere in the mainstream press… retail investors began jumping in… and the rest, as they say, is history.Two months before jumping to the NASDAQ, Cronos' average daily volume was 280,000 shares. Today, its average daily volume is around 16 million shares. That's a 5,600% jump in average volume in 16 months and a direct result of the uplisting.As billions of dollars poured into the stock, the shares soared from $0.25 per share in July 2016 to $25 per share in January 2019 -- a gain of nearly 10,000% in less than three years.These are the stocks I aim to identify -- the ones with the ability to jump 10X in the next few years. These are the kinds of gains that can change your life. Attracting Big MoneyCronos Group isn't the only Pot Jumper Stock out there, but it's one of only a few. Just a handful of companies have made the jump to a major U.S. stock exchange in the last year. Now, they are some of the biggest names in the world when it comes to marijuana stocks.You may have heard of a company called Canopy Growth (NYSE:CGC).It's the largest marijuana company on the planet. All the media outlets love to talk about it. Mostly because it's done nothing but go up in price.Canopy's explosive gains can be traced back to its jump.I first looked at Canopy back in April 2016. It was trading for just $2 per share… and it wasn't on anybody's radar.But I believed Canopy was poised for a huge profit explosion. And sure enough, that's exactly what happened.On May 24, 2018, Canopy became the first marijuana company to trade on the NYSE. The first day of trading was unimpressive to say the least. The stock fell 6% and shortsighted critics concluded that marijuana stocks were not ready for the big time.Well… they couldn't have been more wrong. Just six months later, Canopy had more than doubled.Jumping to a major U.S. stock exchange woke up the big boys -- just like it did with Cronos.In August 2018, multi-billion-dollar alcohol conglomerate Constellation Brands (NYSE:STZ), which is best known for its Corona beer brand, invested $4 billion into Canopy. This followed its initial October 2017 investment of $245 million and gave Constellation a 38% stake in Canopy.And not only did Constellation invest a large amount of money, it did so at a huge 51% premium.So remember when I said I first liked Canopy when it was trading at $2 per share? Today, it has grown into a $14.5 billion behemoth. It traded as high as $59.25 on October 16, 2018 -- which means early investors could have locked in gains of 2,800%+ in just two-and-a-half years. Don't WaitYou can see why I love the legalization trend and the opportunities opening up in marijuana stocks that can make the jump to a major stock exchange.Remember, we're still in the early stages of this jumper phenomenon. I was just in NYC this week at a cannabis conference, and I can tell you that people I spoke with now think it is more likely than before that President Trump will legalize at least some form of marijuana use. Not only would pot stocks in general surge, but the trickle of companies uplisting to major exchanges would turn into a flood.Whether that happens or not, we've uncovered a reliable system for identifying and exploiting what is undoubtedly the biggest -- and often most overlooked -- catalyst in the marijuana markets: cannabis stocks that jump to the major exchanges.My Pot Jumper System has already yielded great results. And now's the perfect time to get in on the action.If you'd like to see how this approach could make virtually anyone a millionaire, then watch this. And you can get my No. 1 cannabis recommendation for free… just for watching.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post How to Know When to Buy Marijuana Stocks appeared first on InvestorPlace.
Famed value investor Bill Nygren, Oakmark portfolio manager, joins 'Fast Money Halftime Report' to discuss General Electric, bank stocks, market sentiment and why he's buying Constellation Brands.
Marijuana M&A heats up, as Canopy buys Acreage. Bruce Linton, Canopy CEO, and Kevin Murphy, Acrage CEO, discuss with CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Steve Grasso and Guy Adami.